Up to 30% of patients prescribed treatment to lower LDL-C are intolerant of statins and discontinue taking them1,2. Additionally, a large segment of the LDL-C population is not at treatment goal3. These patients require additional non-statin therapy or an entirely non-statin alternative.
When considering a non-statin therapy for your patients, whether as add-on or replacement, how important are each of the following traits: oral vs. injectable product, effect on CRP, low risk of new incident diabetes? European and US guidelines differ as do AHA/ACC and AACE/ACE; which guidelines do you follow and why?